Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Late-Breaking Presentations of Initial Results From Phase 2 Studies of Atumelnant (CRN04894) in Congenital Adrenal ...
Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024
Initial Data from Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia to be Presented, Along with Initial Findings ...
Buy Rating Affirmed for Crinetics Pharmaceuticals on Strong Drug Pipeline and Market Potential
H.C. Wainwright analyst Douglas Tsao has reiterated their bullish stance on CRNX stock, giving a Buy rating today. Douglas Tsao has given his ...
Buy Rating for Crinetics Pharmaceuticals: Strong Financials and Promising Clinical Data
Cory Jubinville, PhD, an analyst from LifeSci Capital, maintained the Buy rating on Crinetics Pharmaceuticals (CRNX – Research Report).
Crinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Late-Breaking Presentations of Initial Results From Phase 2 Studies of Atumelnant (CRN04894) in Congenital Adrenal Hyperplasia and ACTH-Dependent Cushing's Syndrome Will be Presented at ENDO June ...
Opko Health (OPK) Q1 2024 Earnings Call Transcript
Hello, and welcome to the OPKO Health first-quarter 2024 financial results conference call. [Operator instructions] Please ...
Crinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on May 10, 2024, the Compensation Committee of Crinetics' Board of Directors granted non-qualified ...
Taiwan News5h
Vietnam Peptide Therapeutics Market Size, Trends, Growth Status, Share, Research, and Forecast to 2024 to 2032
According to the latest report by Report Ocean, titled this “Vietnam Peptide Therapeutics Market” Report gives evaluation and ...